|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's Range||33.31 - 33.75|
|52 Week Range||30.99 - 53.40|
|Beta (3Y Monthly)||1.79|
|PE Ratio (TTM)||9.03|
|Forward Dividend & Yield||0.66 (1.96%)|
|1y Target Est||N/A|
‣ Record Revenue, Margins: Q2 set records on Product Revenue, Total Revenue, Direct Sales and Product Margin. CytoSorbents (CTSO) expects all three to be back online by year-end (one of which resumed ordering in Q2).
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
For many investors looking at marijuana stocks, the name of the game is consumerism. The play is betting on legalization and growing recreational consumer use. It's the reason why marijuana stocks like Canopy Growth (NYSE:CGC) surged on its partnership deal with Constellation Brands (NYSE:STZ). And there is a good reason to be bullish, recreational cannabis usage has the potential to be a multi-billion market over the next decades as more consumers jump onboard.Source: Shutterstock However, there may be a bigger play for investors when it comes to pot stocks. And that's in cannabis medicine.While medical marijuana usage isn't new, deriving new drugs from cannabis is and there are now several biopharma's looking into doing just that. The potential here is just as great as the consumer side. Perhaps even more so. According to research by BDS Analytics, the global medical marijuana market is projected to more than double from 2018 levels in just four short years. Cannabis medicine will be a big driver of that. Investors today have a huge runway of potential ahead of themselves.InvestorPlace - Stock Market News, Stock Advice & Trading TipsHowever, the medical marijuana sector isn't without risk. You basically are combining clinical-stage biotech investing with the volatility of marijuana stocks. But the rewards could be great. * 10 Cyclical Stocks to Buy (or Sell) Now If you have some risk capital to play with, the following three medical marijuana stocks could worth your while. GW Pharmaceuticals (GWPH)Source: GW Pharmaceuticals If you're going to bet on the future of cannabis medicine, why not go with a sure thing. While there are many biotech firms fighting to use cannabis in their drugs, only GW Pharmaceuticals (NASDAQ:GWPH) has one approval under its belt.Getting any drug through the Food and Drug Administration is an amazing feat and about a year ago, GWPH managed to score an approval for its cannabinoid-based drug Epidiolex. The treatment is used to prevent seizures associated with Lennox-Gastaut syndrome or Dravet syndrome.Back in November, the drug was officially launched and so far, it has been quite successful for GWPH. During the firm's reported first quarter, GWPH managed to see Epidiolex sales of $33.5 million. That was more than double analysts' estimates. This puts sales on pace to rake-in more than $150 million this year. Again, that's well above initial analyst estimates. The firm will report its next round of sales figures at the beginning of August.And the blockbusters could keep coming for GWPH. Phase III trial data for Epidiolex and seizures associated with tuberous sclerosis complex (TSC) have recently come in extremely strong. Given the statistical significance of the data, GWPH is looking at another approval for the drug very soon. That could only boost revenues further.Now, shares of GWPH stock are up around 60% year-to-date. But given its long-term potential and overall sales, more gains could be in store. Average analyst targets are about 37% high than its current share price. Cara Therapeutics Inc (CARA)Source: Shutterstock Also surging around 60% this year has been marijuana stock Cara Therapeutics (NASDAQ:CARA). However, unlike GWPH, CARA's rise has all been about the potential for approval.CARA is going after chronic kidney disease-associated pruritus (CKD-aP). Pruritus is a fancy way of saying pain and itching. But for those who suffer from the issue, it can be pretty debilitating. And right now, there isn't a treatment for this instance of the problem. The reason for the investors' enthusiasm is that CARA has been able to see some big initial results from Phase I trials for its drug Korsuva. Phase III trials for the drug should wrap up later this year and given the results so far, CARA could be looking at an approval.That could be big news for the marijuana stock. Over 30 million people have chronic kidney disease (CKD) and analysts project that Korsuva could achieve peak annual sales of more than $570 million. The drug developer has already signed up dialysis specialist Fresenius Medical Care (NYSE:FMS) as a partner to market the drug in its nearly 4,000 centers. Meanwhile, CARA is looking to expand Korsuva beyond injections and into an oral form. That could expand potential sales even further. * 7 Stocks the Insiders Are Buying on Sale All in all, CARA is on a path to approval, has a big addressable market and a plan to grow sales. For investors, the clinical-stage biotech stock could be a good bet for the future of cannabis medicine. Zynerba Pharmaceuticals Inc (ZYNE)Source: Zynerba PharmaceuticalsZynerba Pharmaceuticals (NASDAQ:ZYNE) investors have experienced a staggering gain of 350% this year. And there is plenty of real, lasting "oomph" behind the gains.ZYNE only has one drug candidate -- Zygel -but it is a doozy. The medicine is a cannabidiol (CBD) gel being targeted toward treating seizures and behavioral symptoms associated with neuropsychiatric disorders. We're talking autism and Fragile X syndrome.As a gel, the potential is huge. One of the issues with oral cannabis medications is that they can cause all sorts of gastrointestinal side effects and other liver problems. These problems can build-up over time and for children it can be problematic in the future after years of medicine usage. The firm received a patent for the product last month.Trials are ongoing as well. ZYNE should wrap-up Phase III trials for Zygel for Fragile X at the end of 2019 and file a new drug application during the first half of 2020. The biotech is also conducting phase II trials for the gel for autism. Given the size of the addressable market and the potential for the gel to be a wonder drug for symptoms, the surge in Zynerba could be justified.It's certainly the riskiest of the marijuana stocks on this list, but the firm does have plenty of cash on its balance sheet to make it through its current round of trials and into marketing. And with a small market-cap, there are still plenty of gains to be had.As of this writing, Aaron Levitt did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Cyclical Stocks to Buy (or Sell) Now * 7 Biotech ETFs That Should Remain Healthy * 7 of the Hottest AI Stocks to Buy Now The post 3 Marijuana Stocks to Play the Future of Cannabis Medicine appeared first on InvestorPlace.
Looking at Fresenius Medical Care AG & Co. KGaA's (ETR:FME) earnings update on 30 June 2019, the consensus outlook...
Strong segmental performance and solid 2019 EPS outlook benefit Fresenius Medical's (FMS) Q2 earnings. However, soft performance at Latin America remains a woe.
Let's talk about the popular Fresenius Medical Care AG & Co. KGaA (ETR:FME). The company's shares received a lot of...
CVS Health began a trial of a home dialysis system that could cut into a market controlled by Fresenius Medical and DaVita. But all three stocks fell.
CVS Health said on Wednesday it will start a clinical trial of its new home dialysis system this week, setting it up to compete directly with the two largest operators of U.S. dialysis centers, Fresenius Medical Care AG and DaVita Inc. It had announced last year that it was working on a home hemodialysis system, which would enable patients with end stage renal disease to have more frequent dialysis and potentially better health outcomes compared with clinic-based care. Without a transplant, patients with end-stage kidney disease require dialysis to clear their blood of waste and excess fluid, which involves spending three-to-five hours hooked up to a machine three times a week.
Specifically, the U.S. Department of Health and Human Services has proposed potential changes to reimbursement policy that are likely to encourage home treatment for kidney failure. While the stocks of both companies look cheap following recent underperformance, we think DaVita's nearly 30% discount to our fair value estimate presents a compelling investment opportunity. The two primary modalities amenable to at-home treatment are hemodialysis and peritoneal dialysis.
President Trump signed an executive order Wednesday that will encourage an increase in kidney transplants. This transplant diagnostic company stands to grow significantly, while dialysis companies will take a hit.
Trump's executive order on kidney health boosts business for dialysis companies like DaVita and Fresenius, and pharmaceutical companies like Amgen.
NEW YORK/WASHINGTON, July 10 (Reuters) - The Trump administration on Wednesday set goals to move more kidney disease treatment into patients' homes and increase transplants while reducing the U.S. reliance on more costly dialysis clinics. President Donald Trump signed an executive order underscoring these goals, and the U.S. health agency said it would test new payment structures, including one that rewards end-stage renal disease facilities and doctors who meet targets in these areas. The U.S. government spends $114 billion each year to treat chronic kidney disease and end-stage renal disease.
(Bloomberg Opinion) -- A hodgepodge of news this week is telling the confusing and contradictory story of President Donald Trump’s efforts to change American health care. On Monday, a federal judge blocked the administration’s efforts to force drugmakers to disclose the often astronomical list prices of medicines in their TV ads. It was intended to shame pharma into lowering prices, and would have been the first of the Trump administration’s major drug-cost initiatives to actually take effect. On Tuesday, oral arguments were set for a Department of Justice-backed case that could wipe out the Affordable Care Act. Wednesday will reportedly see the president reveal an ambitious set of initiatives intended to rein in spending on kidney costs. The kidney initiative is among the administration’s better notions, along with its effort to index some drug costs covered by Medicare to the lower prices available abroad. Yet even when the administration lands on a good idea in health care, it seems to get in its own way. The Trump-backed ACA lawsuit, for example, would directly undermine the kidney initiative and price-indexing plan. And while the president has a variety of other proposals in the works – from an effort to pass drug discounts directly to consumers to a plan to force hospitals to make their pricing transparent – many could be exposed to the kind of legal risks that killed the drug-ad initiative. It’s all part of a scattershot and often incoherent approach that isn’t as effective as it could be. Take the kidney-care push: this area of treatment is costly in part because the current system incentivizes expensive care at dialysis centers that are largely run by two companies: DaVita Inc. and Fresenius Medical Care AG. (Peter Grauer, the chairman of Bloomberg LP, is the lead independent director at DaVita.) The Department of Health and Human Services reportedly wants to change that dynamic with new payment models intended to shift patients to more cost-effective treatment at home. At least part of the administration’s ability to implement those models comes from the Center for Medicare and Medicaid Services’ Innovation Center, which was created by the ACA and is threatened by the lawsuit. The contradictions don’t end there. People with end-stage kidney disease are covered by Medicare, so the lawsuit wouldn’t strip their coverage. However, the administration’s plan reportedly emphasizes intervening before people get to the point where they need dialysis or transplants. Killing the ACA is at direct odds with that goal. It would see millions lose insurance coverage, would eliminate protections for people with pre-existing conditions like chronic kidney disease, and crimp access to preventative care. Though it is a long shot, the court case demonstrates the administration’s inconsistency in health care. Just about every health initiative would be harmed by the disruption that would result if this lawsuit succeeds, especially considering that the administration doesn’t have a replacement plan. If it were serious about keeping people off of dialysis or curing HIV, it would oppose this suit and stop other ongoing efforts that harm the ACA’s individual market and Medicaid.The administration hasn’t detailed an ACA alternative because its previous effort to pass one was a political disaster that helped Democrats seize control of the House of Representatives in 2018. Instead, its health-care efforts have largely been confined to executive orders and rule-making. That approach narrows the scope of what the administration can accomplish, and comes with significant risks. If a federal judge thinks that forcing the disclosure of drug prices in ads is an overreach, there’s clearly a chance that the administration’s more ambitious plans will also have issues. I’m rooting for the kidney effort. It targets a real problem and could have an impact, depending on the details. I’d be more optimistic about the plan’s chances if it were part of a cohesive set of policies that had Congressional backing, rather than the current jumble. To contact the author of this story: Max Nisen at email@example.comTo contact the editor responsible for this story: Beth Williams at firstname.lastname@example.orgThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.